CCM® Therapy - Mechanism of Action, Patient Selection and Identification

November 25, 2020

Heart Failure is a progressive disease state previously manageable only by guideline directed medical therapy (GDMT). Many patients are often left without options in their heart failure treatment and require additional screening to determine whether they are a candidate for available device therapy.  In this lecture, Dr. Saltzman moderates and Dr. Kaplan gives an overview of the Optimizer® CCM® therapy delivery system,  indications for use, and shares his best practices on how to screen patients that may benefit from CCM®. Dr. Kaplan also utilizes case studies to emphasize the need for patient screening, as well as give examples of how he implemented CCM® therapy in his practice.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login